Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Non-Current Deffered Revenue: 2013-2023

Historic Non-Current Deffered Revenue for Theravance Biopharma (TBPH) over the last 10 years, with Sep 2023 value amounting to $175,000.

  • Theravance Biopharma's Non-Current Deffered Revenue fell 12.06% to $175,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $175,000, marking a year-over-year decrease of 12.06%. This contributed to the annual value of $192,000 for FY2022, which is 38.06% down from last year.
  • According to the latest figures from Q3 2023, Theravance Biopharma's Non-Current Deffered Revenue is $175,000, which was down 3.31% from $181,000 recorded in Q2 2023.
  • Over the past 5 years, Theravance Biopharma's Non-Current Deffered Revenue peaked at $21.7 million during Q1 2019, and registered a low of $175,000 during Q3 2023.
  • For the 3-year period, Theravance Biopharma's Non-Current Deffered Revenue averaged around $248,818, with its median value being $204,000 (2022).
  • Data for Theravance Biopharma's Non-Current Deffered Revenue shows a maximum YoY plummeted of 96.02% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Theravance Biopharma's Non-Current Deffered Revenue stood at $6.8 million in 2019, then tumbled by 94.85% to $348,000 in 2020, then dropped by 10.92% to $310,000 in 2021, then slumped by 38.06% to $192,000 in 2022, then dropped by 12.06% to $175,000 in 2023.
  • Its last three reported values are $175,000 in Q3 2023, $181,000 for Q2 2023, and $187,000 during Q1 2023.